Hikal Limited (HIKAL)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 15 July 2026

₹240.8 ↓ 30.64% (1Y)

🎯 Key Takeaways

Hikal Limited is in a strategic recovery and repositioning phase within the pharmaceutical and specialty chemicals sector, transitioning from past regulatory and operational setbacks toward sustainable growth. Management is actively rebuilding momentum through capacity expansion, leadership changes, and targeted investments in high-margin segments like Animal Health and CDMO services, aiming to establish a foundation for long-term value creation.
Revenue declined 1.1% QoQ to ₹448 in Q3FY25.
⚠️ Execution risk in large-scale capex plans: The company plans INR900+ crores of future capital expenditure, which must be executed on time and within b

Market Cap

₹2,484

P/E Ratio

33.4

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About HIKAL 📊 Interactive Charts

📖 The Story

Hikal Limited is in a strategic recovery and repositioning phase within the pharmaceutical and specialty chemicals sector, transitioning from past regulatory and operational setbacks toward sustainable growth. Management is actively rebuilding momentum through capacity expansion, leadership changes, and targeted investments in high-margin segments like Animal Health and CDMO services, aiming to establish a foundation for long-term value creation.

📰 What's Happening

Recent filings highlight operational recovery and strategic appointments: On May 27, 2026, Hikal appointed Ravi Khadabadi as President of Crop Protection & Specialty Chemicals, reinforcing focus on high-growth segments. The company also proposed a final dividend of ₹0.60 per share for FY26, contingent on AGM approval (Filing: CORPORATE ACTION | 2026-05-27). Additionally, shareholders are being invited to vote via postal ballot on the appointment of Sandip Parikh as Independent Director (Filing: VOTING RESULTS | 2026-06-04), with voting open until July 4, 2026. Management emphasized recovery from FDA compliance delays, improved capacity utilization to 80-85%, and sequential margin expansion, particularly in Q4 FY26 where EBITDA margin reached 20.3% and Crop Protection revenue grew 45% QoQ. The company is targeting 15-20% CAGR in revenue by FY27-FY30, supported by INR900+ crores of planned capex and expansion into specialty chemicals and CDMO partnerships.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	545	388	435	448	514	407	453	448
Operating Profit	88	51	59	65	95	59	75	76
OPM %	16.1%	13.0%	13.2%	14.5%	18.4%	14.3%	16.5%	16.1%
Net Profit	36	7	13	16	34	5	18	17
EPS	₹2.92	₹0.56	₹1.02	₹1.31	₹2.76	₹0.41	₹1.48	₹1.39

Hikal's financial trajectory shows signs of stabilization after a period of margin pressure and revenue volatility. While consolidated revenue declined 8% YoY to ₹1,713 crores in FY26 (from ₹1,867 crores in FY25), EBITDA margin compressed to 12.9% from 17.7% in FY25, the trend in quarterly performance reveals improvement. Sequential growth was evident in Q4 FY26, with revenue of ₹519 crores and PAT of ₹14 crores, up from pre-exceptional ₹55 crores, driven by 45% QoQ growth in Crop Protection and 60% sequential growth in Pharmaceutical revenue to ₹629 crores. EBITDA rose to ₹105 crores with a 20.3% margin in Q4 FY26. Earlier quarters in FY25 showed stable operating performance with OPM around 16%, but FY26 saw margin compression due to exceptional items including a ₹38 crore impairment and labor code adjustments. Despite this, capacity utilization improved to 80-85%, and the company reported strong volume growth and margin recovery in key segments, indicating underlying operational resilience.

🔮 Management Outlook & What's Next

Management expressed a clear long-term growth vision, targeting 15-20% CAGR in top-line revenue by FY27-FY30 and a ROCE of 18-20%, underpinned by INR900+ crores of planned capital expenditure. Key initiatives include expanding the Panoli facility to support 5-6 DMF filings by Q4 2026, scaling the Animal Health segment to INR500+ crores in 4-5 years, and commercializing new products in Specialty Chemicals and Personal Care from FY27 onwards. Management highlighted sustained margin improvement as a key expectation, driven by operational upgrades, higher capacity utilization, and strategic focus on CDMO partnerships and high-value specialty products. These forward-looking statements were consistently reiterated across recent filings, including the FY26 results announcement on June 3, 2026.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Execution risk in large-scale capex plans: The company plans INR900+ crores of future capital expenditure, which must be executed on time and within budget to achieve growth targets. Delays or cost overruns could pressure returns. 2. Regulatory and compliance exposure: Past FDA-related setbacks and ongoing Supreme Court investigations into environmental liabilities introduce uncertainty, despite management’s assertion of no material liabilities. 3. Margin sustainability: While EBITDA margin improved to 20.3% in Q4 FY26, it compressed from 17.7% in FY25. Sustaining margin gains will depend on successful product commercialization and pricing power in competitive segments. 4. Market concentration: Revenue dependence on Crop Protection and Pharmaceuticals exposes the company to sector-specific volatility, including pricing pressures and demand fluctuations.

📋 Recent Filings

🧠 Analyst's Read

Hikal is transitioning from a turnaround phase to a growth trajectory, supported by operational improvements, leadership changes, and strategic capex. While near-term profitability faces headwinds from exceptional items and margin compression, the company’s clear long-term targets and reinvestment focus present a compelling case for recovery. Investors should monitor execution of the Panoli expansion, commercialization timelines for new products, and margin trends in high-growth segments as key near-term catalysts.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on HIKAL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when HIKAL files new disclosures

Track HIKAL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track HIKAL — Free

Free account · 2 AI queries/day